Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Approves First Biosimilar Of 2018

By Catherine Sbeglia | May 16, 2018

The approval of Pfizer’s Retacrit marks the FDA’s first biosimilar approval of 2018.

Retacrit (epoetin alfa-epbx) is a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.

“With Retacrit’s approval, the FDA is delivering on its promise to increase momentum around biosimilar approvals. Biosimilars are making great strides in the U.S., mostly from positive changes to policy and reimbursement,” says Rick Lozano, VP of Biosimilars & Integrated Business Development at AmerisourceBergen.

Lozano, though, is also careful to point out that while this approval is exciting, there are still challenges facing the biosimilar marking. However, he goes on to say that there are “incentives that are crucial for the success of biosimilars, like rebates currently reserved for biologics,” and “this latest approval is encouraging as it builds on the success and learnings of past launches.”

He also comments that manufacturers have gotten better at determining how to be competitive as the market changes, stating, “biosimilars need to be distributed in all channels to ensure adequate patient access, and providers need to be educated on the safety and efficacy of the product.”

Moving forward, Lozano believes that significant cost savings are possible if the FDA enacts policies that speed up the process of bringing biosimilars to market.

For more information, please visit: Retacrit.

(Source: The U.S. Food and Drug Administration)


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE